Aura Biosciences, Inc. cash flow to debt ratio of -487.67% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Aura Biosciences, Inc.'s free cash flow has decreased 5.10% from $-81.06M last year to $-85.19M, signaling decreasing performance

Aura Biosciences, Inc.'s debt to equity ratio is 0.05, which means that the company's assets are healthy financed, signaling financial stability.

Aura Biosciences, Inc.'s debt has decreased relative to shareholder equity from 0.12 last year to 0.05 today, signaling strengthened financials

Aura Biosciences, Inc. has a net cash position, so leverage is healthy.

Aura Biosciences, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Aura Biosciences, Inc. has insufficient data to evaluate this check.

Aura Biosciences, Inc.'s short-term assets of $149.74M exceed its short-term liabilities of $18.38M

Aura Biosciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Aura Biosciences, Inc.'s return on equity of -73.18%, is lower than 15.00%, indicating bad performance

Aura Biosciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Aura Biosciences, Inc. has insufficient public price history to evaluate earnings stability.

Aura Biosciences, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Aura Biosciences, Inc. has negative free cash flow, indicating cash burn

Aura Biosciences, Inc.'s yearly earnings has decreased 22.17% since last year from $-86.92M to $-106.19M, signaling decreasing performance

Aura Biosciences, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -27.12% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Aura Biosciences, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Aura Biosciences, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Aura Biosciences, Inc. has insufficient public price history to evaluate ROE consistency.

Aura Biosciences, Inc. has insufficient data to evaluate this check.

Aura Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Aura Biosciences, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Aura Biosciences, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Aura Biosciences, Inc. has insufficient data to evaluate this check.

Aura Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Aura Biosciences, Inc. has a price-to-book ratio of 2.32x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Aura Biosciences, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue